TRED Research Brief FY 2016

Sponsored Funding The university’s sponsored funding for research, community service, and teaching/training activities totaled $86,949,073 for FY 2016. Over the past decade, total active external funding increased by 109 percent, from $41.5 million in FY 2007 to $87 million in FY 2016. Of the FY 2016 total, 50 percent or $52,504,629 supports research, and 40 percent or $34,375,005 is funded by the federal government. The university is receiving funding from 105 agencies and organizations. The Halmos College of Natural Sciences and Oceanography is the largest recipient of sponsored funding with 44 percent of the total, followed by 29 percent to the College of Osteopathic Medicine. In FY 2016, there were 176 proposals processed through the NSU Office of Sponsored Programs. Leading Therapeutic Areas in Clinical Research DENTIFRICES AND IMPLANTS College of Dental Medicine PEDIATRIC CONSTIPATION, CHRONIC FATIGUE SYNDROME College of Osteopathic Medicine PREVALENCE OF VITREOMACULAR DISEASE College of Optometry NUTRACEUTICAL INTERVENTION FOR OXIDATIVE STRESS College of Pharmacy NUTRACEUTICAL INTERVENTION Mailman Segal Center for Human Development NUTRACEUTICAL SUPPLEMENTATION IMPACT ON BODY COMPOSITION College of Health Care Sciences ORTHOPEDIC DEVICES FOR METASTATIC BONE CANCER H. Thomas Temple, M.D. NSU Technologies NSU is able to recognize high-potential technologies, assess their technical and commercial feasibility, secure patent protection, and conduct transactions with commercialization partners for the ultimate benefit of the public. NSU technologies that are ready for commercialization include • portfolio of abuse-deterrent pharmaceutical compositions • diagnostic for genetic mutations • early detection of bed sores • fall prediction model • therapies for treatment of heart failure • image compression and encryption • portfolio of small-molecule cancer therapeutics • portfolio of novel drug delivery methods for anaphylaxis • novel method to diagnose complex immune diseases • novel method for modulating oncolytic viruses